Month 3: Representative cytostatic drugs to be studied were selected (WP8, M 15)
Month 12: Validated analytical methods (LC, GC) for the determination of the selected model compounds were developed (WP2; M4)
Month 16: Results from acute tests, that are needed for establishing dose ranges for chronic exposure tests completed (WP5; M8).
Month 18: Cytotoxicity of cytostatic drugs determined & dose ranges for further genotoxicity and gene expression in vitro studies were established (WP6; M10)
Month 24: Predictive transcript signature database for 5-FU is established (WP7; M13)
Month 30: PHARMAS Cluster Conference organised
Month 40: All environmental samples collected and distributed to the partners for chemical and toxicological analyses (WP3; M5)